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A Ab bs st tr ra ac ct t
I In nt tr ro od du uc ct ti io on n. . The aim of the study is to evaluate the incidence and phenotype - genotype characteristics of
hereditary colorectal cancer syndromes in Latvia in order to develop the basis of clinical management for patients
and their relatives affected by these syndromes. M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s. . From 02/1999-09/2002 in several
hospitals in Latvia cancer family histories were collected from 865 patients with CRC. In families suspected of
having a history consistent with a hereditary colorectal cancer syndrome, DNA testing for MLH1, MSH2 and
MSH6 genes was performed. In addition immunohistochemical (IH) examination of the normal and cancer
tissue from large bowel tumors for MSH2 and MSH6 protein expression was performed prior to DNA analysis.
R Re es su ul lt ts s. . From the 865 CRC cases only 3 (0.35%) pedigrees fulfilled the Amsterdam II criteria of Hereditary
Nonpolyposis Colorectal Cancer (HNPCC) and 15 cases (1.73%) were suspected of HNPCC. In 69 cases (8%)
with a cancer family aggregation (CFA) were identified. Thus far 27 IH analyses have been performed and in
3 cancers homogenous lack of MSH2 or MSH6 protein expression was found. In one of these cases a mutation
in MSH6 was identified. In 18 patients suspected of HNPCC or of matching the Amsterdam II criteria, denaturing
high performance liquid chromatography (DHPLC) followed by DNA sequencing of any heteroduplexes of the
35 exons comprising both MLH1 and MSH2 was performed revealing 3 mutations. 
For all of kindreds diagnosed definitively or with a high probability of being an HNPCC family appropriate
recommendations concerning prophylactic measures, surveillance and treatment were provided in written form.
C Co on nc cl lu us si io on ns s. . Existing pedigree/clinical data suggest that in Latvia the frequency of HNPCC is around 2% of
consecutive colorectal cancer patients. It is crucial that genetic counseling is an integral part of cancer family
syndrome management.
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I In nt tr ro od du uc ct ti io on n
During the last decade dramatic changes have
taken place in the diagnosis and management of
familial/hereditary colorectal cancer syndromes. New
developments are offering possibilities of early cancer
detection, improvements in treatment and preventive
measures for the affected and persons at risk of
disease. Hereditary cancer management has developed
as an essential part of modern oncology treatment and
current practice reveals the importance of cancer
genetic services in providing the best care for hereditary
cancer syndrome patients. 
Latvia is an East European country located in the
Baltic  region  with  approximately  2.4  million  of
inhabitants. In the year 2002 there were 8977 new
cancer cases detected in Latvia, including 926 colorectal
cancer cases. From all newly diagnosed cancers only
17.4% were detected in stage I, and 22.9% in stage of
the II disease. According to epidemiological data
available for familial colorectal cancer, one would expect
somewhere in between 90 and 130 familial cases in
Latvia annually. From this estimate, 20-60 of them are
most likely to be associated with hereditary condition
(either HNPCC or FAP). Detection and appropriate
management of patients affected with disease or those
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with an increased risk of developing it would provide a
considerable improvement in oncology care in Latvia.
Active investigations and research into hereditary
cancers in Latvia began almost ten years ago [1].
However, clinical work on hereditary cancer syndromes
became more widely accepted in 1998, when the
Department of Surgery, Riga Stradins University was
invited to participate in the European Commission
funded  Copernicus  multicenter  project  entitled:
Phenotype - genotype correlations in HNPCC and MENI
(IC15 – CT98 – 0305). Since its success was readily
apparent the international collaboration was extended
within the EC 5
th framework programme – Development
of network of cancer family syndrome registries in
Eastern Europe (QLRI-CT-1999-00063). During the 2
nd
year of this project, the Hereditary Cancer Institute of
Riga Stradins University was established. The main aim
of this institution is to study the hereditary cancer
syndromes in the population of Latvia and to introduce
the obtained knowledge into clinical practice.
In the following article we would like to report results
of this study, which is taking place in the framework of
the hereditary colorectal cancer program in Latvia. The
aim of the study is to evaluate the incidence and
phenotype/genotype  characteristics  of  hereditary
colorectal cancer syndromes in Latvia in order to develop
a rational basis for the clinical management of patients
and their relatives affected by these syndromes. 
M Me et th ho od ds s
From February 1999 to September 2002 cancer
family histories were collected from 865 patients with
colorectal cancer in the largest oncology hospitals of
Latvia. Patients completed questionnaires that included
questions, which asked: Had your relatives (father,
mother, grandparents, siblings, children, grandchildren,
aunts, uncles) been diagnosed with any tumor? What
was the localization of the tumor? At what age was the
tumor detected? 
Criteria applied for the diagnosis of hereditary
colorectal cancers are summarized in Table 1.
In individuals from families matching criteria for
hereditary colorectal cancer syndromes, genetic testing
for MLH1, MSH2 and MSH6 mutations using DHPLC
and concomitant DNA sequencing of all heteroduplexes
was performed [8-13] after obtaining written informed
consent from each patient. If material was available
immunohistochemical examination of the normal and
cancer tissue from large bowel for MSH2 and MSH6
protein  expression  was  performed  before  DNA
sequencing. The Ethics Commission, Riga Stradins
University, accepted the protocol for the study.
R Re es su ul lt ts s
From  the  865  colorectal  cancer  patients  402
(46.47%) cases did not report any malignancy in their
families. In 463 (53.53%) colorectal cancer cases there
was at least one malignancy among blood relatives.
Only 3 (0.35%) pedigrees fulfilled the Amsterdam II
criteria. Unfortunately, histopathological confirmation
of  cancer  in  affected  family  members  of  those  3
pedigrees was not possible. One patient (0.12%) fulfilled
late onset HNPCC criteria. Fourteen individuals (1.62%)
matched the criteria of suspected HNPCC. In 41
T Ta ab bl le e   1 1. .   Diagnostic criteria for hereditary colorectal cancer syndromes
N No o. . H He er re ed di it ta ar ry y   s sy yn nd dr ro om me e D Di ia ag gn no os st ti ic c   c cr ri it te er ri ia a
1. Definitive HNPCC [2, 3, 4] Amsterdam II criteria: 
1) at least 3 relatives affected by HNPCC associated cancer (colorectal, endometrial, small
bowel, ureter, renal pelvis); at least one should be the first degree relative of the other two; 
2) at least two successive generations should be affected; 
3) at least one cancer should be diagnosed before the age of 50; 
4) familial adenomatos polyposis (FAP) should be excluded; 
5) tumors should be verified by pathological examination
2. Late onset HNPCC Amsterdam II criteria without age limitation
3. Suspected HNPCC [5, 6] 1) at least 2 first degree relatives with HNPCC associated cancer 
(colorectal, endometrial, small bowel, urinary tract); 
2) at least one cancer should be diagnosed before the age of 50
4. Familial colorectal  1) Colorectal cancer in at least 2 first or second degree relatives; 
cancer (FCC) [7] 2) colorectal cancer diagnosed at relatively young age; 
3) HNPCC and FAP should be excluded
5. Cancer familial  at least 3 first degree blood relatives with malignancy of any localization
aggregation (CFA)
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(4.74%) patients the suspicion of familial colorectal
cancer was diagnosed. In 69 cases (8%) CFA was
detected.  Currently,  27  immunohistochemical
examinations have been performed. In 3 tumors MSH2
or MSH6 protein expression was homogenously negative
suggesting a germline mutation in either one of these
genes. In 1 of these cases mutation in MSH6 gene (exon
4, 1815-1816delTA) was detected. The pedigree of this
family  matched  late  onset  HNPCC  criteria.  In  an
additional 25 patients DNA sequencing of MLH1 and
MSH2 genes was performed. One MLH1 and two MSH2
mutations were identified. The pedigree of the family
with a mutation in MLH1 (ex12 (G/A 1409+1 out of
frame del) is shown on Fig. 1. Due to lack of any medical
confirmation for cancer diagnosis in the probands’
relatives this pedigree was classified as belonging to the
CFA syndrome. 
Two  hMSH2  mutations  were  detected  in  ex3
(C508T;  Gln170Stop)  and  ex12  (c.1786delAAT;
596delAsn) respectively. Both families fulfilled the
suspected HNPCC criteria.
For all of the families with HNPCC diagnosed by
the Amsterdam II criteria or within high probability
group, appropriate recommendations concerning
prophylactic measures, surveillance and treatment were
elaborated and transmitted in written form. 
D Di is sc cu us ss si io on n
Every  year  in  Latvia  approximately  900  new
colorectal cancer cases are diagnosed. During our
study period we have collected cancer family histories
from about 30% of the total number of cases. The
initial intention was to collect cancer family histories
from all consecutive cases in the principal oncology
hospitals of Latvia, but due to a variety of different
reasons  (patient’s  refusals,  limited  capacities  of
research group etc.) this was not possible. 
Our group of colorectal cancer patients is, however,
comparable to the total group of newly diagnosed
colorectal cancer patients as far as age, gender,
nationality, place of residence and clinical stage are
concerned. Therefore our colorectal cancer group can
be considered as representative for all newly diagnosed
colorectal cancer patients in Latvia and can be used
in pilot epidemiological studies. On the basis of 865
cancer family histories the incidence of HNPCC in the
population of Latvia is somewhere between 0.5-2% of
all colorectal cancers. According to several other
studies, the incidence of HNPCC varies considerably
from 1% to 10% of all colorectal cancers in different
populations and ethnic groups [6, 9, 14-19]. It appears
that clinical incidence of HNPCC in Latvia is one of the
lowest reported. This estimate is supported by molecular
evidence where two MSH2 and only one of each
MLH1/MSH6 mutations were detected. There is no
data available about the incidence of hereditary
colorectal cancer syndromes in neighboring countries
like Estonia and Lithuania. However there are published
data on 3 and 6 families, respectively, which fulfills the
Amsterdam II criteria or suspected HNPCC criteria from
Estonia and Lithuania. In 2 Lithuanian families and one
Estonian family mutations in MLH1 and MSH2 genes
were detected [5]. Results of a prospective multicenter
epidemiological study of HNPCC in Finland reveals
that the frequency of hereditary nonpolyposis colorectal
cancer is between 0.7-2.4%, which is very similar to
the frequency observed in our study [20]. 
Unfortunately, we cannot exclude bias related to
the poor reliability of collected pedigree information.
Many families have small numbers of relatives and they
have very poor medical information about one another
for several different historical reasons. 
None of the first four mutations identified in the
Latvian  population  were  similar  to  the  founder
mutations identified in Lithuania or Poland [5], however,
the number of mutations currently detected does not
allow for any ultimate conclusion. 
In Table 2 the mutation rate and clinical HNPCC
detection rate in specific age groups is presented. From
4 mutations 2 were identified in probands in an age
group between 30-39 years, which corresponds to a
younger age of HNPCC diagnosis [21]. The only
HNPCC family (with rare mutation in MSH2 gene) in
F Fi ig g. .   1 1. .   Pedigree of the MLH1 (c.1409+1G/A) family; Tr, transversum;
Ut,  uterus;  FGT,  female  genital  tract;  The  numbers  following
abbreviations indicate the age of cancer diagnosis; Arrow indicates
the proband
T Tr r3 34 4
U Ut t5 50 0
d d5 55 5
F FG GT T
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Latvia detected by another working group in 1997 was
also  found through a proband with a CRC diagnosed
at the age of 34. According to the data obtained it is
very  important  to  screen  actively  for  hereditary
syndromes all colorectal cancer patients in the age
group of 30-39 years as the mutation detection rate
in our series is relatively high (18.2%).
C Co on nc cl lu us si io on ns s
 Development of hereditary colorectal cancer program
in  Latvia  is  a  result  of  successful  international
collaboration in the framework of scientific projects
of the European Commission.
 According to cancer family history data and DNA testing
results the incidence of HNPCC in Latvia is ~ 2%. 
 Genetic counseling should be the integral part of
any cancer family syndrome program. 
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